Compare PSN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | LEGN |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 5.9B |
| IPO Year | 2019 | 2020 |
| Metric | PSN | LEGN |
|---|---|---|
| Price | $62.74 | $22.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $85.29 | $69.58 |
| AVG Volume (30 Days) | 2.2M | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.02 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $6,494,748,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.83 |
| Revenue Next Year | $4.29 | $51.27 |
| P/E Ratio | $28.65 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $54.56 | $21.19 |
| 52 Week High | $97.91 | $45.30 |
| Indicator | PSN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.79 | 32.41 |
| Support Level | $60.00 | $21.19 |
| Resistance Level | $62.21 | $28.97 |
| Average True Range (ATR) | 2.76 | 1.19 |
| MACD | -0.41 | 0.01 |
| Stochastic Oscillator | 11.14 | 19.41 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.